EpiEndo Pharmaceuticals is a clinical stage pharmaceutical company with a unique focus on impairment of epithelial barriers as a common mechanism of many inflammatory conditions such as the airway, gastrointestinal tract tract and skin.

EpiEndo is a clinical stage pharmaceutical company with a unique focus on impairment of epithelial barriers as a common mechanism of many inflammatory conditions such as the airway, GI tract and skin.

EpiEndo Pharmaceuticals is pleased to announce that it is the recipient of this year’s Rising Star Award at the Swedish American Life Science Summit (SALSS).

EpiEndo Pharmaceuticals Secures EUR 20 Million Series A Funding to Advance Clinical Development of its Non-Antibiotic Macrolide for the treatment of COPD

EpiEndo Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel non-antibiotic macrolide therapeutics for the treatment of inflammatory disorders, is announced as the winner of the Biotech & Pharmaceuticals category, at the European Innovation Council Investor Day on Health 2021.

EpiEndo Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel non-antibiotic macrolide therapeutics for the treatment of inflammatory disorders, announced today that it is the recipient of a €2.7 million convertible loan agreement from the European Innovation Council (EIC) Fund.

First-in-Human Clinical Trial of EpiEndo’s Lead Compound, EP395, for Chronic Inflammatory Airway Diseases Commences at the Medicines Evaluation Unit in Manchester, UK.

EpiEndo Pharmaceuticals is pleased to announce the appointment of Dr. Sigríður Valgeirsdóttir and Robert Helgason to the Company’s Board of Directors.

EpiEndo Pharmaceuticals is pleased to announce that their consortium project EPIcoliX has been officially recognized as a Eurostar labelled project.